COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01336244
Recruitment Status : Completed
First Posted : April 15, 2011
Last Update Posted : October 18, 2011
Information provided by (Responsible Party):
Galapagos NV

Brief Summary:
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses (MAD) of GLPG0778 given to healthy subjects for 13 days compared to placebo, and to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0778 after multiple oral administrations.

Condition or disease Intervention/treatment Phase
Healthy Drug: GLPG0778 Drug: placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0778 in Healthy Male Subjects
Study Start Date : April 2011
Actual Primary Completion Date : August 2011
Actual Study Completion Date : September 2011

Arm Intervention/treatment
Experimental: GLPG0778 ascending doses
Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
Drug: GLPG0778
capsules containing 50 or 100 mg of GLPG0778

Placebo Comparator: Placebo
Twice daily for 13 days, matching the scheme of the multiple ascending dose.
Drug: placebo
multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule

Primary Outcome Measures :
  1. Occurrence of adverse events [ Time Frame: Daily during treatment, up to 10 days postdose ]
    At every study visit, subjects will be asked whether any adverse events have occurred since start of treatment.

  2. Evaluation of hematological, biochemical and cardiovascular parameters. [ Time Frame: until 10 days postdose. ]
    On predefined timepoints during the study blood and urine samples will be taken, and cardiovascular tests (ECG, blood pressure, heart rate) recorded to assess whether the test compound causes any deviation.

Secondary Outcome Measures :
  1. Pharmacokinetics of repeated doses [ Time Frame: 24 hours postdose ]
    Bloodsamples are taken on various timepoints to assess how much of the study drug is taken up in the blood (absorption), how long it stays in the blood (excretion), and whether any "breakdown"-products of the drug are present (metabolism).

  2. Pharmacodynamics (PD) of GLPG0778 [ Time Frame: up to 10 days postdose ]
    To explore biomarkers of GLPG0778 activity after repeated oral administrations.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy male, age 18-50 years
  • body mass index (BMI) between 18-30 kg/m², inclusive.

Exclusion Criteria:

  • significantly abnormal platelet function or coagulopathy
  • smoking
  • drug or alcohol abuse
  • hypersensitivity to any of the test substances

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01336244

Layout table for location information
SGS Stuivenberg
Antwerp, Belgium
Sponsors and Collaborators
Galapagos NV
Layout table for investigator information
Study Director: Gerben van 't Klooster, PhD Galapagos NV
Principal Investigator: Lien Gheyle, MD SGS Stuivenberg
Layout table for additonal information
Responsible Party: Galapagos NV Identifier: NCT01336244    
Other Study ID Numbers: GLPG0778-CL-102
2011-000892-16 ( EudraCT Number )
First Posted: April 15, 2011    Key Record Dates
Last Update Posted: October 18, 2011
Last Verified: October 2011
Keywords provided by Galapagos NV: